Skip to main content

Kairos Pharma, LTD.

corporate_fare Company Profile

Kairos Pharma, LTD.

KAPA·NYSE·Life Sciences·CIK 0001962011

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company has leveraged molecular insights of the mechanisms of therapeutic resistance and immune suppression to develop a new class of novel drugs that it expects will target drug resistance and checkpoints of immune suppression. Its seven-drug portfolio offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Its proprietary technologies are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. and ranked number one in California and number two in the nation in U.S. News & World Report's Best Hospitals Honor Roll for 2022-2023. As of the date of the Annual Report, its product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator. The product portfolio currently consists of five pre-clinical or clinical-trial stage drug candidates developed by the company and designed to target immune response; two therapeutic agents developed by its Enviro Therapeutics, Inc. subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents; and a variety of technologies licensed by its Enviro Therapeutics, Inc. subsidiary consisting of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. The human immune system can tell the difference between normal cells in the body and those it sees as "foreign," which allows it to focus an attack on the foreign cells while leaving the normal cells alone.

Kairos Pharma, LTD. (NYSE:KAPA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for KAPA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for KAPA spans PRE 14A, 10-Q, 8-K.

Recent high-impact activity:

  • Kairos Seeks Vote to Lift Equity Plan to 20M Shares, Shield Pool From Reverse Splits
  • Kairos Q3 10-Q: Going Concern Warning, $3.1M Cash, Material Weakness Persists
  • Kairos Amends Helena Equity Line, Extends Term to 2028; Reports 17.7-Month PFS

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$5.45M
Diluted EPS
-$0.30
Op. Cash Flow
-$3.44M
Operating Income
-$5.57M
Cash & Equivalents
$4.49M
Debt / Equity
0.00×
Shares Outstanding
20.82M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014159

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 84,066 shares in KAPA as of the October 30, 2026 settlement, a 37.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 8.7% of KAPA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)84,066 shares as of October 30, 2026
Change vs prior period▼ 37.5%
Days to cover1.00 at avg daily volume of 110,928
Daily short volume (FINRA facilities)8.7% of 17,358 shares on November 20, 2026
5-day average short volume25.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$0.4002 -8.19% today
52-week range · as of 2026-11-20 $0.3808 – $7.28
Market cap
$2.04M
Volume
33.8K (0.3× avg)
3-mo avg 101.2K
Live data · 2026-11-22 10:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KAPA - Latest Insights

KAPA
Nov 20, 2026, 5:30 PM EST
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.4068
Real-time Price: $0.4002 info
Change: -$0.0066 (-2%) info
Market Cap: $2.042M info
KAPA
Nov 13, 2026, 5:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.465
Real-time Price: $0.4002 info
Change: -$0.0648 (-14%) info
Market Cap: $2.042M info
KAPA
Nov 03, 2026, 11:50 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4751
Real-time Price: $0.4002 info
Change: -$0.0749 (-16%) info
Market Cap: $2.042M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets